Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-26-006061
Filing Date
2026-08-06
Accepted
2026-08-06 16:30:39
Documents
46
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR JUN 2026 xenetic_i10q-063026.htm   iXBRL 10-Q 528902
2 CONSULTING AGREEMENT BETWEEN RND PHARM INTEL DOO AND XENETIC BIOSCIENCES xenetic_ex1002.htm EX-10.2 48304
3 CERTIFICATION xenetic_ex3101.htm EX-31.1 10064
4 CERTIFICATION xenetic_ex3102.htm EX-31.2 10139
5 CERTIFICATION xenetic_ex3201.htm EX-32.1 4093
  Complete submission text file 0001683168-26-006061.txt   2968410

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE xbio-20260630.xsd EX-101.SCH 18611
7 XBRL CALCULATION FILE xbio-20260630_cal.xml EX-101.CAL 24433
8 XBRL DEFINITION FILE xbio-20260630_def.xml EX-101.DEF 87698
9 XBRL LABEL FILE xbio-20260630_lab.xml EX-101.LAB 203894
10 XBRL PRESENTATION FILE xbio-20260630_pre.xml EX-101.PRE 170885
50 EXTRACTED XBRL INSTANCE DOCUMENT xenetic_i10q-063026_htm.xml XML 296218
Mailing Address 945 CONCORD ST. FRAMINGHAM MA 01701
Business Address 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Filer) CIK: 0001534525 (see all company filings)

EIN.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37937 | Film No.: 261249700
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)